We have recently seen mixed news on TEAD inhibitors. Sporos BioDiscovery announced that they would be presenting two posters highlighting preclinical data from the company’s novel, TEAD1 / TEAD4 inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in early April. Stephen Rubino, Ph.D., President of Sporos BioDiscovery said:
“We look forward to presenting two posters at this year’s AACR meeting that highlight the significant preclinical work we have done to characterize SPR1 as a potential best-in-class TEAD inhibitor. In addition, our team’s expert biological analysis has uncovered a new therapeutic vulnerability that could broaden the potential use of SPR1, a TEAD1/4 inhibitor, to a new subset of cancers with certain homozygous deletions.”